Clinigen Group plc has partnered with Mitsubishi Tanabe Pharma Corporation (‘MTPC’), to initiate a Managed Access Program (also known as an Early Access Program) in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (‘ALS’).
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Mitsubishi Tanabe Pharma Corporation (‘MTPC’), to initiate a Managed Access Program (also known as an Early Access Program) in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (‘ALS’).
Edaravone is approved for use as a treatment for ALS in Japan, South Korea and the USA.
ALS is an idiopathic neurodegenerative disease in which motor neurons selectively degenerate and vanish. Muscle strength declines throughout the entire body, including the limb, facial, and respiratory muscles, and muscular atrophy progress. The cause for the majority of cases is not well understood, but may involve genetic and environmental factors. It is one of the best known neuromuscular diseases and affects approximately two in 100,000 people worldwide.
John Lagus, Head of Managed Access, Clinigen, said:
“We are pleased to once again be working with MTPC to help eligible patients in Europe gain access to this important medicine.
“As the trusted global leader in access to unlicensed medicines, this partnership aligns with our mission of getting the right medicines to the right patient at the right time.”
Healthcare professionals can obtain details about the edaravone Managed Access Program by calling the medicine access team at +44 1283 494 340, or emailing medicineaccess@clinigengroup.
About edaravone
Edaravone is a free-radical scavenger that was discovered by Mitsubishi Tanabe Pharma. It was approved by the Ministry of Health, Labor and Welfare in April 2001 as a treatment agent for the acute stage of cerebral infarction. In Japan, it is being marketed under the product name RADICUT®. Edaravone has the effect of scavenging free radicals that arise accompanying cerebral ischemia, controlling the lipid peroxidation reaction, and protecting neurons in the region of the ischemia and the surrounding region. Accordingly, it is thought that edaravone has the effect of scavenging free radicals, which increase in ALS, protecting motor neurons from oxidative stress, and delaying the decline in muscle strength and the progress of muscular atrophy.
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com
Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation is a research-based pharmaceutical company, created through the merger of Tanabe Seiyaku Co., and Mitsubishi Pharma Corporation on 1st October 2007, based in Osaka, Japan.
Mitsubishi Tanabe Pharma Corporation is committed to becoming a global research-driven pharmaceutical company, which continuously brings new medicines to market that meet global needs.
| Contact details Clinigen Group plc Instinctif Partners |
Tel: +44 (0) 1283 495010
Tel: +44 (0) 20 7457 2020 |
